Brief Enhanced Anxiety Sensitivity Treatment (BEAST) for Anxiety

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
VA Fingerlakes Healthcare System, Canandaigua, NY
Anxiety+3 More
Brief Enhanced Anxiety Sensitivity Treatment (BEAST) - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This pilot study trial will test the acceptability, feasibility, and usability of a brief enhanced anxiety sensitivity treatment to reduce anxiety sensitivity and functional impairment in Veterans.

Eligible Conditions

  • Functional Impairment
  • Anxiety

Treatment Effectiveness

Study Objectives

3 Primary · 6 Secondary · Reporting Duration: Baseline, immediately post-intervention, one month post-intervention, three month post-intervention

Baseline, immediately post-intervention, one month post-intervention, three month post-intervention
Coronavirus Impact Battery - Behavior Scales - assessing change throughout the study
Coronavirus Impact Battery - Worry Scales - assessing change throughout the study
Depression Symptom Index Suicidality Scale (DSI-SS) - assessing change throughout the study
Functional Impairment Due to COVID (FIDC) - assessing change throughout the study
Intolerance of Uncertainty-12 (IUS-12) - assessing change throughout the study
PROMIS Profile-29 - assessing change throughout the study
WHO Disability Assessment 2.0 (WHODAS 2.0) - assessing change throughout the study
Baseline, immediatly post-intervention, one month post-intervention, three month post-intervention
Anxiety Sensitivity Index-3 (ASI-3) - assessing change throughout the study
Daily, from baseline to post-intervention for a total of two weeks, then for one week following one month follow-up and three month follow-up
Anxiety, Depression, Distress Inventory-27 (ADDI-27) - assessing change throughout the study
Brief Penn State Worry Questionnaire - PSWQ - assessing change throughout the study
Short Scale Anxiety Sensitivity Index (SSASI) - assessing change throughout the study
Screening
Blessed Orientation Memory Concentration Test (BOMC)
immediately post-intervention
Program Satisfaction Questionnaire (PSQ)

Trial Safety

Trial Design

1 Treatment Group

BEAST Intervention
1 of 1
Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: Brief Enhanced Anxiety Sensitivity Treatment (BEAST) · No Placebo Group · N/A

BEAST Intervention
Behavioral
Experimental Group · 1 Intervention: Brief Enhanced Anxiety Sensitivity Treatment (BEAST) · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, immediately post-intervention, one month post-intervention, three month post-intervention
Closest Location: VA Fingerlakes Healthcare System · Canandaigua, NY
Photo of new york 1Photo of new york 2Photo of new york 3
N/AFirst Recorded Clinical Trial
0 TrialsResearching Anxiety
0 CompletedClinical Trials

Who is running the clinical trial?

Canandaigua VA Medical CenterLead Sponsor
11 Previous Clinical Trials
1,909 Total Patients Enrolled
VA Office of Research and DevelopmentFED
1,459 Previous Clinical Trials
2,748,898 Total Patients Enrolled
16 Trials studying Anxiety
1,777 Patients Enrolled for Anxiety
Nicholas Allan, PhDPrincipal InvestigatorVA Fingerlakes Healthcare System

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a life expectancy of at least 18 years.
You have a score of 5 or more on the WHODAS 2.0.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.